Nam augue velit, fermentum sed erat non, efficitur interdum lectus. Donec hendrerit lorem a dui euismod tempus. Vivamus auctor blandit tellus et interdum.
Biotechnology Quality Systems Enable 100% Batch Release Rate
Client / Setting: Emerging Diagnostics Company | Novel IVD Platform
The Challenge
First‑time FDA submission for novel IVD platform with limited regulatory experience, incomplete clinical validation, unclear predicate device strategy, and aggressive market entry timeline.
The Solutions
End‑to‑end 510(k) strategy including predicate analysis, substantial equivalence justification, clinical study design/execution, performance testing, labeling development, and FDA submission management.
Key Results
FDA 510(k) clearance obtained in 4.5 months (no additional information requests)
Successful market launch 6 months ahead of competitor
$15M first‑year revenue enabled by regulatory clearance
Why It Matters
Demonstrates ability to navigate complex FDA pathways efficiently, enabling faster time‑to‑market and competitive advantage.
Highlights
Clinical validation study designed and executed (500 samples)
Comprehensive risk analysis per ISO 14971
Pre‑submission meeting strategy secured FDA alignment
Use Case Request Form Biotechnology Quality Systems Enable 100% Batch Release Rate
